Excellent article. I've owned the stock for several years on this exact thesis, and it's been the financial equivalent of a poke in the eye with a sharp stick. CLSD has become a case study in the risks of owning an undercapitalized med-tech developer that's dependent on larger partners for commercialization. Suprachoroidal delivery is a no brainer for patients, but it's very disappointing for investors to see the developer of such compelling technology now circling the drain.
Great summary - impressed by your work!
I opened a position today and I am already fearful!
Excellent article. I've owned the stock for several years on this exact thesis, and it's been the financial equivalent of a poke in the eye with a sharp stick. CLSD has become a case study in the risks of owning an undercapitalized med-tech developer that's dependent on larger partners for commercialization. Suprachoroidal delivery is a no brainer for patients, but it's very disappointing for investors to see the developer of such compelling technology now circling the drain.
Yeah in hindsight they overplayed their hands developing therapies of their own instead of out-licensing technology as a low-cost-shell.
But let´s see, there are some chapters left to write here.